Impact of ErbB2 and RB Pathways on DCIS Progression and Treatment

描述（申请人提供）：目前在筛查人群中，导管原位癌（DCIS）占新诊断乳腺癌的20-30%。由于无法对复发和疾病进展高风险的DCIS人群进行分层，许多妇女目前接受了过度治疗，尽管进行了手术和辅助干预，但仍有大约10-15%的患者复发。初步和已发表的数据表明，大部分DCIS病变表现出ErbB2和rb通路的改变。然而，尚无研究调查同一DCIS病变中两种通路异常的影响。在本应用中我们采用功能研究法，将：2.明确RB通路在ErbB2过表达DCIS进展中的作用。确定RB和ErbB2状态如何影响放射治疗反应。

DESCRIPTION (provided by applicant): Currently ductal carcinoma in situ (DCIS) accounts for 20-30% of newly diagnosed breast cancers in screened populations. Because of the inability to stratify the DCIS populations at high risk for recurrence and disease progression, many women are currently over-treated and approximately 10-15% patients have disease recurrence despite surgical and adjuvant interventions. Preliminary and published data indicate that a large fraction of DCIS lesions exhibits alterations in the ErbB2 and RB-pathways. However there are no studies investigating effects of both pathways abnormalities in the same DCIS lesion. In this application we using functional studies, will: 1. Define role of RB pathway in progression of ErbB2 overexpressing DCIS and 2. Determine how RB and ErbB2 status impacts response to radiation therapy.